“Global Respiratory Inhalers Market Set to Grow to $38bn by 2023” says new Visiongain report
09 April 2019
Visiongain has launched a new pharma report Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies.
The global respiratory inhalers market is estimated to reach $38bn in 2023. In the respiratory Inhalers market the top three companies by revenue are GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, with 57.1% of the world market in 2018.
Inhalation therapy is the best option for lung diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). These local therapies allow the use of smaller doses and reduce systemic side effects. In the last two decades, a remarkable scientific interest in the technology for pulmonary delivery was spiked by the fact that the lungs can be used as a portal for systemic drug delivery.
The lead analyst of the report commented "Developments in treatment are expected to continue as new drugs and emerging technologies become more widely available. This may include personalised treatments for certain types of asthma not responding to the stepwise approach of the Global Initiative for Asthma (GINA) guidelines and treatments tailored to the specific composition of individual patient’s airway inflammation.
Inhaler technology will continue to innovate with ‘intelligent’ delivery systems allowing more precise targeting of specific areas of the lungs becoming more common. In addition, inhaler-based health monitoring devices providing feedback of inhaler use to patients and healthcare professionals offer the promise of improved treatment adherence and health outcomes."
Leading companies featured in the report include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987.
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Recent News
Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034
The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034
26 March 2024
Read
Visiongain Publishes Medical Imaging Devices Market Report 2024-2034
The global Medical Imaging Devices market was valued at US$ 54.3 billion in 2024 and is projected to grow at a CAGR of 4.6% during the forecast period 2024-2034.
20 March 2024
Read
Visiongain Publishes Women’s Health Market Report 2024-2034
The global Women’s Health market was estimated to be valued at US$ 61 billion in 2034 and is expected to register a CAGR of 4.6% from 2024 to 2034.
18 March 2024
Read
Visiongain Publishes Clinical Trial Supplies Market Report 2024-2034
The global Clinical Trial Supplies market is estimated at US$4,146.7 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period 2024-2034.